Floatz logo

Ratg

Myeloproliferative Disorders

Hackensack Meridian HealthPhase 3Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Myeloproliferative Disorders cohort.

Asset / SponsorPhaseRating
Treg Cells
Stanford University
Phase 2B
Inno-206
OHSU Knight Cancer Institute
Phase 2B
Donor Lymphocyte Preparation Depleted Of Host Functional Alloreactive T-Cells
Kiadis Pharma
Phase 2/3CCC
Mesna
Center for International Blood and Marrow Transplant Research
Phase 2CCC
(+)-VINCRISTINE
National Cancer Institute (NCI)
Phase 2CCC

View all 22 →

Same molecule, other indications

Ratg is also rated in:

Acute Myelogenous LeukemiaDormant
CCC
Indicative ·
51 / 100
View asset →
Myelodysplastic SyndromeDormant
CCC
Indicative ·
48 / 100
View asset →
Chronic Myelogenous LeukemiaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →